Clinical trials: Allergies
Gingivitis, Periodontitis
Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP
90-day, self-controlled, longitudinal, non-blinded clinical trial which will measure changes in clinical parameters in participants with gingivitis and Stage I or II periodontitis who apply ClōSYS® Sensitive Fluoride Toothpaste…
- Trial name
- NCT05258721
- Testing
- ClōSYS® Sensitive Fluoride Toothpaste, ClōSYS® Sensitive Rinse
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Rowpar Pharmaceuticals, Inc.
Aging
CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy
The purpose of this study is to test the hypothesis that two years of sustained 25% caloric restriction (CR) in men age 21-50 (inclusive) and women age 21-47 (inclusive) will slow aging and protect against age-related disease…
- Trial name
- NCT00427193
- Testing
- Caloric Restriction (CR), Control
- Where
- 3 sites in United States
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Duke University
Rhinitis, Allergic, Perennial, Allergic Rhinitis
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber…
- Trial name
- NCT00848965
- Testing
- Fluticasone propionate
- Where
- Austria
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Asthma
Study to Investigate the Efficacy of Symbicort® SMART.
The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus…
- Trial name
- SAKURA (NCT00839800)
- Testing
- Symbicort Turbuhaler, Terbutaline Turbuhaler
- Where
- 109 sites in Argentina, Brazil and 10 more
- Volunteers
- 2,091 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD
This clinical trial will investigate the effectiveness and safety of a new active ingredient (LEO 138559) in the treatment of moderate to severe atopic dermatitis (AD). It is given by subcutaneous injection.
- Trial name
- NCT05470114
- Testing
- LEO 138559, Dupixent®
- Where
- Austria
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Asthma
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma
The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with…
- Trial name
- NCT01244984
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 30 sites in Japan
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
Asthma, Obesity
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
- Trial name
- GLITZ (NCT00787644)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Vermont
Ovarian Cancer, Breast Cancer
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic…
- Trial name
- SOLI (NCT04330040)
- Testing
- Olaparib
- Where
- 16 sites in India
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)
This is a 3-part study to assess the safety, tolerability, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of MK-8226 in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT01732510
- Testing
- MK-8226
- Volunteers
- 65 people
- Sponsor
- Merck Sharp & Dohme LLC
Allergic Conjunctivitis
Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
The purpose of this study is to evaluate the effectiveness and safety of Olopatadine Hydrochloride (HCl) ophthalmic solution 0.1% versus Epinastine HCl ophthalmic solution, 0.05% in a population of healthy, adult Japanese…
- Trial name
- NCT02251613
- Testing
- Olopatadine HCl ophthalmic solution, 0.1%, Epinastine HCl ophthalmic solution, 0.05%
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Sacroiliac Joint Pain, Sympathetically Maintained Pain
Effect of Sedation on Diagnostic Injections
Interventional pain procedures have diagnostic, prognostic and therapeutic value. It is well-documented that the reference standard for identifying a pain generator is a low-volume block performed with local anesthetic, with or…
- Trial name
- NCT01472835
- Testing
- Midazolam, Fentanyl
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Johns Hopkins University
Rhinitis, Allergic, Perennial, Asthma
Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)
There is currently no effective way to prevent development of allergic rhinitis (nasal allergies) and asthma and no cure. Sublingual immunotherapy (SLIT), a type of therapy in which allergens are placed under the tongue, may be a…
- Trial name
- NCT00829985
- Testing
- Glycerinated German Cockroach Allergenic Extract
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADmIRe (NCT03831191)
- Testing
- LY3375880
- Where
- 58 sites in United States, Argentina and 11 more
- Volunteers
- 136 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with…
- Trial name
- ATLAS (NCT05155085)
- Testing
- AK002
- Where
- 55 sites in United States, Germany
- Volunteers
- 131 people
- Sponsor
- Allakos Inc.
Asthma
Non-Interventional Study to Describe the Clinical Management in Asthmatic Patients (NICMA)
Asthma is a heterogenic chronic disease that affects more than 300 million people worldwide, which it's characterized by acute symptomatic episodes of varying severity, including intermittently inflammation and narrowing of the…
- Trial name
- (NICMA) (NCT06811155)
- Where
- Spain
- Volunteers
- 288 people
- Sponsor
- Hospital Universitario Virgen de la Victoria
Asthma
Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma
This study will include the patients who are Japanese children with bronchial asthma aged 5 years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at about 29 centres.
- Trial name
- NCT00509028
- Testing
- Budesonide, Conventional Asthma Therapy
- Where
- Japan
- Volunteers
- 241 people
- Sponsor
- AstraZeneca
Immunologic Desensitization
Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy
The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.
- Trial name
- NCT02676765
- Testing
- allergen extract tablet
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Atopic Dermatitis
Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1)
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of…
- Trial name
- NCT04146363
- Testing
- Lebrikizumab
- Where
- 94 sites in United States, Australia and 8 more
- Volunteers
- 424 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
To compare the efficacy of olaparib in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian cancer.
- Trial name
- NCT01081951
- Testing
- olaparib, paclitaxel, carboplatin
- Where
- 53 sites in United States, Australia and 11 more
- Volunteers
- 162 people
- Sponsor
- AstraZeneca
Asthma
A Randomized Trial Examining the Effectiveness of Mobile-Based Asthma Action Plans vs. Paper Asthma Action Plans
The purpose of this study is to see if using a mobile phone application asthma action plan will help improve asthma management.
- Trial name
- PEAK2 (NCT02091869)
- Testing
- Paper Asthma Action Plan, Mobile Phone
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Arkansas Children's Hospital Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.